536565 NOVELIX

Novelix Pharmaceuticals Share Price

 

 

Start SIP in NOVELIX

Start SIP

Performance

  • Low
  • ₹60
  • High
  • ₹62
  • 52 Week Low
  • ₹24
  • 52 Week High
  • ₹70
  • Open Price₹61
  • Previous Close₹60
  • Volume2,417
  • 50 DMA₹56.99
  • 100 DMA₹51.36
  • 200 DMA₹42.07

Investment Returns

  • Over 1 Month + 10.31%
  • Over 3 Month + 48.75%
  • Over 6 Month + 34.37%
  • Over 1 Year + 146.38%

Smart Investing Starts Here Start SIP with Novelix Pharmaceuticals for Steady Growth!

Invest Now

Novelix Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 99
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 96
  • P/B Ratio
  • 3.5
  • Average True Range
  • 3.43
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.89
  • RSI
  • 50.38
  • MFI
  • 58.95

Novelix Pharmaceuticals Financials

Novelix Pharmaceuticals Technicals

EMA & SMA

Current Price
₹59.50
0 (0%)
pointer
  • Bearish Moving Average 8
  • Bullish Moving Average 8
  • 20 Day
  • ₹59.80
  • 50 Day
  • ₹56.99
  • 100 Day
  • ₹51.36
  • 200 Day
  • ₹42.07

Resistance and Support

59.4 Pivot Speed
  • R3 64.41
  • R2 62.71
  • R1 61.10
  • S1 57.79
  • S2 56.09
  • S3 54.48

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Novelix Pharmaceuticals Ltd has an operating revenue of Rs. 84.87 Cr. on a trailing 12-month basis. An annual revenue growth of 578% is outstanding, Pre-tax margin of 0% needs improvement, ROE of 0% is poor and needs improvement. The company has a debt to equity of 53%, which is bit higher. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 52% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 15% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 70 which is a FAIR score but needs to improve its earnings, a RS Rating of 95 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 119 indicates it belongs to a poor industry group of Food-Packaged and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Novelix Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-13 Quarterly Results
2025-08-14 Quarterly Results & A.G.M.
2025-06-24 Others Inter alia, to consider and approve 1. The conversion of Warrants into Equity Shares of the Company.
2025-05-27 Audited Results
2025-04-12 Others Inter-alia, to consider 1. Convening of an EGM for appointment of Non-Executive Independent Director of the Company. 2. To appoint a scrutinizer for the upcoming EGM. 3. Other business matters.

Novelix Pharmaceuticals F&O

Novelix Pharmaceuticals Shareholding Pattern

51.98%
42.69%
5.33%

Novelix Pharmaceuticals FAQs

Novelix Pharmaceuticals share price is ₹59 As on 09 January, 2026 | 13:45

The Market Cap of Novelix Pharmaceuticals is ₹96 Cr As on 09 January, 2026 | 13:45

The P/E ratio of Novelix Pharmaceuticals is 99 As on 09 January, 2026 | 13:45

The PB ratio of Novelix Pharmaceuticals is 3.5 As on 09 January, 2026 | 13:45

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23